Efficacy of rapid IV administration of valproic acid for status epilepticus
- 25 January 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 64 (2), 353-355
- https://doi.org/10.1212/01.wnl.0000149527.47600.5a
Abstract
Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.Keywords
This publication has 10 references indexed in Scilit:
- Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive SeizuresEpilepsia, 2003
- Safety and tolerance of rapidly infused Depacon®: A randomized trial in subjects with epilepsyEpilepsy Research, 2003
- Intravenous Valproate in Status EpilepticusAnnals of Pharmacotherapy, 2001
- The Safety of Rapid Valproic Acid InfusionEpilepsia, 2000
- Intravenous valproate is well tolerated in unstable patients with status epilepticusNeurology, 2000
- Safety of rapid intravenous infusion of valproate loading doses in epilepsy patientsEpilepsy Research, 1999
- Safety of high intravenous valproate loading doses in epilepsy patientsJournal of Epilepsy, 1998
- A Comparison of Four Treatments for Generalized Convulsive Status EpilepticusThe New England Journal of Medicine, 1998
- Persistent Nonconvulsive Status Epilepticus After the Control of Convulsive Status EpilepticusEpilepsia, 1998
- Status EpilepticusThe New England Journal of Medicine, 1998